NTS-WBRT in Brain Metastases
ConditionBrain Metastases
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorMassachusetts General Hospital
About this trial
This research is being done to assess the quality of life and symptom burden in participants who receive (normal tissue sparing whole brain radiation therapy (NTS-WBRT).
This research study involves:
* NTS-WBRT (normal tissue sparing whole brain radiation therapy) * Memantine standard of care drug
Eligibility criteria
Qualifiers
Any patient with a solid tumor diagnosis and any number of brain metastasis clinically indicated for cranial irradiation with whole brain radiation therapy
Age ≥ 18
Karnofsky Performance Status ≥ 70
Prior stereotactic radiosurgery (SRS) permissible per physician discretion
Disqualifiers
Leptomeningeal disease (by any one or more of clinical assessment, radiographic assessment, or cerebrospinal fluid study)
Prior whole brain radiation therapy
Pre-existing or current use of memantine or other NMDA antagonists
Known allergy to contrast used in imaging studies and/or inability to have MRI imaging
Trial design
Treatments tested in this trial
- NTS-WBRT (normal tissue sparing whole brain radiation therapy)
- Memantine
Treatment groups
41 Participants
are divided into 1 treatment groupLocations
1Massachusetts General Hospital Cancer Center02114, BostonMassachusetts, United States
Sponsors and collaborators
Massachusetts General Hospital
Lead sponsor
Source ClinicalTrials.gov